** Shares of Australia's Neurizon Therapeutics NUZ.AX fall as much as 5.9% to A$0.08, their lowest level since November 23, 2023
** Marks steepest intraday pct fall since December 23
** Biotech company says the U.S. Food and Drug Administration denies its request for Fast Track Designation
** Request was for its investigational new treatment for Amyotrophic Lateral Sclerosis, NUZ-001
(Reporting by Anjali Singh in Bengaluru)
((anjali.singh2@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.